Get notified of page updates
Education > XRAY > Hereditary Cancer Risk

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

Hereditary Cancer Risk

81 through 90 of 127

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Article : The right not to know when not knowing is dangerous

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: People with Icelandic heritage

Healthcare providers are bound by the guiding principle of doing no harm. But how does this concept apply to their patients who have not consented to genetic testing or who do not want to know their results? In that case, is providing test results more harmful or not? Anna Clausen explores these issues in the context of breast cancer gene testing in her Global Health Now article “The Right Not to Know: When Ignorance is Bliss but Deadly.” (4/20/18)

Read More

Relevance: Medium-High

Strength of Science: Medium

Study : Take your time, follow your heart: strategies for communication about family planning

Relevance: Medium-High

Strength of Science: Medium

Most relevant for: Young high risk women

When a woman is newly diagnosed with a BRCA mutation, she faces many risk management decisions. Although many of these decisions impact family planning, little guidance is available on how to communicate this information. This study examines female previvors’ advice on effective strategies for discussing family planning decisions. (03/28/18)

Read More

Relevance: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Update : FDA approves at-home test kits for inherited cancer: how useful are they?

Relevance: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People who are considering or have had direct-to-consumer testing through 23andMe

Genetic testing for health conditions (such as risk for cancer) typically requires a prescription from a doctor. Until recently, direct-to-consumer (DTC) genetic testing has focused on tests to learn your ancestry and find of unknown branches of family trees. A laboratory called 23andMe that provides direct-to-consumer genetic testing has been given FDA approval to report results for 3 mutations found in the BRCA1 and BRCA2 genes. The FDA statement provides details about this approval and warns people about the limitations of the 23andMe test. (03/19/18)

Read More

Relevance: Medium-High

Quality of Writing: Medium

Article : Insurance companies are more than curious about your genetic test results

Relevance: Medium-High

Quality of Writing: Medium

Most relevant for: People considering testing for an inherited gene mutation

An article on CBSNews.com addressed why insurance companies, particularly long-term insurance companies, might want to know which of their policy holders and potential policy holders have a gene that raises their risk for cancer. The article discusses genetic discrimination by insurance companies that provide long term care policies. Federal laws protect people with gene mutations from discrimination in health insurance. No such federal laws exist for life insurance, disability insurance or long term care. (3/13/18)

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Should biannual MRIs replace annual mammograms in high-risk women?

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women at increased risk for breast cancer due to an inherited mutation

The risk of breast cancer is exceptionally high in women who have a personal or family history of breast cancer or who carry a mutation in BRCA or certain other genes. More frequent screening is one strategy for early detection of breast cancer for these women. Study results presented at the 2017 San Antonio Breast Cancer Symposium suggest that MRI screening every 6 months may be more effective than the currently recommended annual breast MRI and annual mammogram in detecting early stage breast cancers-which are more treatable-in high-risk women. (2/1/18)

Read More

Relevance: Medium-Low

Strength of Science: Medium-Low

Research Timeline: Human Research

View Related Clinical Trials

Study : No new high-risk breast cancer genes here

Relevance: Medium-Low

Strength of Science: Medium-Low

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with a family history of breast cancer but no known inherited mutation

While some of the genes that cause hereditary breast cancer are known (for example, inherited mutations in genes like BRCA, ATM and PALB2), others remain unidentified. Two studies found 72 DNA changes (also known as “variants” or “SNPs”) that affect breast cancer risk. These variants are different from mutations in genes that dramatically increase cancer risk. Most of these new variants are located outside of the portion of DNA that is used to make proteins. Further research is needed on these new variants before they can be used by doctors to help people understand and manage their risk for cancer. (1/12/18)

Read More

Relevance: High

Strength of Science: Medium-High

Study : Birth control and breast cancer risk among younger women

Relevance: High

Strength of Science: Medium-High

Most relevant for: Young women on, or considering taking hormonal birth control

On December 7, 2017 the New England Journal of Medicine published results from a study by Lina Mørrch of the University of Copenhagen and colleagues showing that hormonal contraceptives (birth control) increase the risk of breast cancer. The study is unique because it is one of the first to specifically assess the breast cancer risk associated with newer, low-dosage methods of contraception. The large and significant effort analyzed medical data of nearly 1.8 million young women in Denmark on average for over 10.9 years. Results were covered widely in the U.S. by many major media outlets, including the New York Times, USA Today, Forbes and Time.  (12/14/17)

Read More

Relevance: Medium-High

Quality of Writing: High

Article : Dense breasts and mammograms: Jill Goodacre’s story

Relevance: Medium-High

Quality of Writing: High

Most relevant for: Women with dense breast tissue on mammograms

Korin Miller’s piece for SELF magazine focuses on why women with dense breasts may need more than a screening mammogram. Miller highlights the recent story in People magazine of Jill Goodacre, a former Victoria’s Secret model and the wife of recording artist and talk show host Harry Connick Jr. Goodacre told of her breast cancer diagnosis 5 years ago after having additional screening of her dense breast tissue following a normal mammogram.  (12/8/17)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Genetic counseling by phone or face-to-face

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People referred to a genetic counselor or those considering genetic testing

Results presented at the 2017 American Psychological Association’s annual meeting showed genetic counseling by telephone is as “safe and effective” in long-term psychological and social outcomes compared to traditional in-person counseling for women at risk for hereditary breast and ovarian cancer. This presentation is an update on research published in 2014. (11/29/17)

Read More

Relevance: Medium-High

Quality of Writing: High

View Related Clinical Trials

Article : Preimplantation genetic diagnosis and hereditary cancer

Relevance: Medium-High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: people with an inherited mutation linked to cancer risk

Andrew Joseph’s piece for STAT, “A baby with a disease gene or no baby at all: Genetic testing of embryos creates an ethical morass,” focuses on  preimplantation genetic diagnosis (PGD) and the emerging ethical issue in the field of reproductive medicine: What to do when patients seeking to get pregnant select embryos with DNA that could lead to a disease or a disability.  (11/8/17)

Read More

This Portal Sponsored By:

CDC